Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
9 Meters Biopharma Inc
(NQ:
NMTR
)
0.0722
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 9 Meters Biopharma Inc
< Previous
1
2
3
Next >
9 Meters Biopharma, Inc. to Present at 2021 BIO Digital
June 09, 2021
RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference
June 01, 2021
RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection
May 26, 2021
- Larazotide supplied to study authors under an FDA-approved Expanded Access Program - - Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
May 18, 2021
This version of the release contains a corrected hyperlink. RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
May 18, 2021
RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO,...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome
May 17, 2021
RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021
May 13, 2021
- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit
April 21, 2021
RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome
April 19, 2021
RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study
April 12, 2021
RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.